期刊
EMBO MOLECULAR MEDICINE
卷 5, 期 10, 页码 1569-1585出版社
WILEY
DOI: 10.1002/emmm.201302621
关键词
anti-inflammatory; dystrophy; mdx; membrane injury; muscle
资金
- United States Department of Defense [W81XWH-05-1-0616, W81XWH-09-1-0218, W81XWH-11-1-0754]
- Foundation to Eradicate Duchenne
- Muscular Dystrophy Association USA
- National Institutes of Health [R01-AR050478, 1U54HD053177-01A1, RO1AR055686]
- T32 postdoctoral training grant in the Genetics and Genomics of Muscle [5T32AR056993-02]
- NIH [K26OD011171]
- MDA
- US Department of Defense [W81XWH-05-1-0659, W81XWH-11-1-0782]
- Parent Project Muscular Dystrophy
Absence of dystrophin makes skeletal muscle more susceptible to injury, resulting in breaches of the plasma membrane and chronic inflammation in Duchenne muscular dystrophy (DMD). Current management by glucocorticoids has unclear molecular benefits and harsh side effects. It is uncertain whether therapies that avoid hormonal stunting of growth and development, and/or immunosuppression, would be more or less beneficial. Here, we discover an oral drug with mechanisms that provide efficacy through anti-inflammatory signaling and membrane-stabilizing pathways, independent of hormonal or immunosuppressive effects. We find VBP15 protects and promotes efficient repair of skeletal muscle cells upon laser injury, in opposition to prednisolone. Potent inhibition of NF-B is mediated through protein interactions of the glucocorticoid receptor, however VBP15 shows significantly reduced hormonal receptor transcriptional activity. The translation of these drug mechanisms into DMD model mice improves muscle strength, live-imaging and pathology through both preventive and post-onset intervention regimens. These data demonstrate successful improvement of dystrophy independent of hormonal, growth, or immunosuppressive effects, indicating VBP15 merits clinical investigation for DMD and would benefit other chronic inflammatory diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据